TECH · Bio-Techne Corp
$72.35
+0.38% last session
End-of-day data · close of 2026-09-11
Market cap
$11B
Enterprise value
$11B
Trailing P/E
62.1
Forward P/E
31.3
Dividend yield
0.0%
Beta
1.27
Avg volume
5M
Employees
3K
Daily Change %
0.38%
5 Days Change
-0.25%
10 Days Change
-0.08%
30 Days Change
0.25%
60 Days Change
1.44%
Month to Day Change
0.10%
Year to Day Change
23.38%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TECH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-13
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$73.00
+1.3% vs priceRBC Capital
Sector Perform$73.00
+1.3% vs priceCitigroup
Neutral$73.00
+1.3% vs priceUBS
Buy$79.00
+9.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Wells Fargo | Downgrade | Overweight → Equal-Weight | $62.00 → $73.00 |
| 2026-07-09 | RBC Capital | Downgrade | Outperform → Sector Perform | $62.00 → $73.00 |
| 2026-06-30 | TD Cowen | Downgrade | Buy → Hold | $65.00 → $73.00 |
| 2026-06-30 | Benchmark | Downgrade | Buy → Hold | $0.00 |
| 2026-06-29 | Citigroup | Downgrade | Buy → Neutral | $70.00 → $73.00 |
| 2026-06-26 | Stephens & Co. | Downgrade | Overweight → Equal-Weight | $68.00 → $73.00 |
| 2026-06-26 | William Blair | Downgrade | Outperform → Market Perform | $0.00 |
| 2026-06-26 | Baird | Maintains | Neutral | $49.00 → $73.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.6% above the 50-day MA ($71.90).
- Price vs 200-day MA: Trading 18.4% above the 200-day MA ($61.12).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($72.47).
TECH Price Chart
Loading chart for TECH…
Fundamentals
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.